Related Experiment Video
Updated: Feb 13, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
Published on: October 25, 2024
In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or
R De Vecchis1,2, C Ariano3,4, G Di Biase5
1Preventive Cardiologyand Rehabilitation Unit, DSB 29 "S. Gennaro dei Poveri Hospital", via S.Gennaro dei Poveri 25, 80136, Napoli, Italy. devecchis.erre@virgilio.it.
Insights
Reduced doses of sacubitril/valsartan are safe for heart failure patients intolerant to maximum doses. This approach did not increase mortality or hospitalizations for heart failure compared to target doses.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with reduced ejection fraction (HFREF) management involves gradual sacubitril/valsartan titration.
- Dose reduction or interruption is recommended for patients experiencing tolerability issues.
Purpose of the Study:
- To estimate the proportion of patients on minimum or intermediate sacubitril/valsartan doses.
- To compare all-cause mortality and heart failure hospitalizations between patients on optimal and sub-maximum sacubitril/valsartan doses.
Main Methods:
- Retrospective analysis of 68 HFREF patients on sacubitril/valsartan, beta-blockers, and mineralocorticoid receptor blockers.
- Identified 20 patients (29.4%) with contraindications for full-dose sacubitril/valsartan.
- Assessed outcomes in patients maintained on reduced (minimum/intermediate) versus target doses.
Main Results:
- After a median 5.25-month follow-up, no significant difference in all-cause mortality risk was observed between reduced and target dose groups (OR=1.666, p=0.6266).
- Patients on reduced sacubitril/valsartan doses showed a similar risk of heart failure hospitalizations compared to those on target doses (OR=0.789, p=1.00).
Conclusions:
- In HFREF patients intolerant to maximum sacubitril/valsartan doses, reduced doses did not elevate all-cause mortality.
- Reduced sacubitril/valsartan dosing did not increase heart failure hospitalizations compared to target doses over a median follow-up of 5.25 months.
Introduction:
In heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen. Nevertheless, if patients exhibit tolerability problems, a provisional reduction of the dose of sacubitril/valsartan or even its interruption are recommended.
Material And Methods:
This study provides estimates of respective proportions of patients receiving minimum or intermediate doses of sacubitril/valsartan. In addition, a comparison was made to detect possible differences regarding all-cause mortality and heart failure hospitalization in patients treated with the recommended optimum dose compared to those receiving submaximum maintenance doses of sacubitril/valsartan.
Results:
Patients treated with sacubitril/valsartan in addition to beta-blocker and mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were identified as having clinical features that were contraindications to the administration of sacubitril/valsartan at full dose. The subsequent decision was to maintain an intermediate dose in 11 patients and to reduce the dose to the minimum level allowed, i.e., 24 mg/26 mg twice daily in nine patients. After a median follow-up of 5.25 months, no differences were found concerning the risk of all-cause death by comparing patients treated with reduced versus those subjected to target doses of sacubitril/valsartan (odds ratio [OR] = 1.666; 95% confidence interval [CI] = 0.256-10.823; p = 0.6266). Patients taking reduced doses had a similar risk of heart failure hospitalizations when compared to patients treated with the target dose (OR = 0.789; 95% CI: 0.077-8.0808; p = 1.00).
Conclusion:
During a median follow-up of 5.25 months, in the group of patients who had proven to be intolerant to the maximum dose of sacubitril/valsartan, use of reduced doses of the drug did not result in increased all-cause mortality or heart failure hospitalization compared to patients treated with sacubitril/valsartan at the target dose.
Related Concept Videos
Hospitals-II
Nurses that work in...
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Hospitals-I
Bioavailability Study Design: Single Versus Multiple Dose Studies
Increasing Function

